This case involves a procedural decision by the Court of First Instance of the Unified Patent Court regarding a patent dispute between GlaxoSmithKline (GSK) and a conglomerate of Pfizer and BioNTech entities (PBNT). The dispute centers on patent EP2590626, which is held by GSK. PBNT requested the court to limit GSK's auxiliary requests (ARs) to ten, claiming that the current number of 42 ARs is excessive and asking for an extension to file their responses. GSK defended its position, arguing that the number of ARs is justified by the complexity of the case and associated invalidity attacks. The court ordered GSK to provide a detailed table of its ARs, while denying PBNT's request to limit the ARs. The court also considered, but did not completely grant, PBNT's request for an extension, emphasizing the need for expeditious proceedings under the UPC framework.